Tracing the sentinel node

SentoClone AB is a Swedish biotech company developing a patented immunotherapy for cancer treatment based on autologous T lymphocytes extracted from the sentinel node, the first tumour draining lymph node. The sentinel node is resected in conjunction with tumour reducing surgery.
The extracted lymphocytes are cultivated in vitro and activated. The activated lymphocytes multiply and are given back to the patient after 4 to 6 weeks by a simple transfusion.
So far, more than 110 patients have been treated. As the therapy is based on autologous cells, significant side effects are not expected and have not been seen.
A randomised controlled phase II study in advanced malignant melanoma has recently been started and further studies are planned in other indications.

Please visit www.sentoclone.com or www.mynewsdesk.com/se/pressroom/sentoclone for more information.

Category:

Science & Technology

Tags:

• sentoclone
• tracing sentinel node
• sentinel node
• immunotherapy
• cell therapy